AN2 Therapeutics, Inc. (ANTX) insider trading

{
  "status": "OK",
  "results": [
    {
      "tickers": [
        "ANTX"
      ],
      "issuer_cik": "0001880438",
      "owner_cik": "0001914883",
      "accession_number": "0001193125-26-389545",
      "form_type": "4",
      "filing_date": "2026-09-11",
      "period_of_report": "2026-09-09",
      "issuer_name": "AN2 Therapeutics, Inc.",
      "issuer_trading_symbol": "ANTX",
      "owner_name": "Readnour Robin Shane",
      "is_director": true,
      "is_officer": false,
      "is_ten_percent_owner": false,
      "is_other": false,
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-09-09",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 585,
      "transaction_price_per_share": 6.0243,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 624765,
      "transaction_value": 3524.2155000000002,
      "direct_or_indirect": "I",
      "nature_of_ownership": "See footnotes",
      "footnotes": [
        {
          "id": "F2",
          "description": "The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners QP 2018, LP (\"MGC 2018 QP\") on April 23, 2026."
        },
        {
          "id": "F3",
          "description": "Represents the weighted average sale price for multiple transactions ranging from $6.02 to $6.04, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein."
        },
        {
          "id": "F4",
          "description": "MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."
        },
        {
          "id": "F6",
          "description": "Shares held directly by MGC 2018 QP."
        }
      ]
    },
    {
      "tickers": [
        "ANTX"
      ],
      "issuer_cik": "0001880438",
      "owner_cik": "0001914883",
      "accession_number": "0001193125-26-389545",
      "form_type": "4",
      "filing_date": "2026-09-11",
      "period_of_report": "2026-09-09",
      "issuer_name": "AN2 Therapeutics, Inc.",
      "issuer_trading_symbol": "ANTX",
      "owner_name": "Readnour Robin Shane",
      "is_director": true,
      "is_officer": false,
      "is_ten_percent_owner": false,
      "is_other": false,
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-09-09",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 523,
      "transaction_price_per_share": 6.0243,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 557467,
      "transaction_value": 3150.7089,
      "direct_or_indirect": "I",
      "nature_of_ownership": "See footnotes",
      "footnotes": [
        {
          "id": "F1",
          "description": "The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP (\"MGC 2018 LP\") on April 23, 2026."
        },
        {
          "id": "F3",
          "description": "Represents the weighted average sale price for multiple transactions ranging from $6.02 to $6.04, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein."
        },
        {
          "id": "F4",
          "description": "MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."
        },
        {
          "id": "F5",
          "description": "Shares held directly by MGC 2018 LP."
        }
      ]
    }
  ]
}

// trimmed to 2 results

The response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.